Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Stock Information for Nabriva Therapeutics plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nabriva Therapeutics plc

Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Arbutus to Participate in Two Upcoming Investor Conferences
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
Arbutus to Participate in Jefferies Global Healthcare Conference
Arbutus to Present Imdusiran Data at EASL Congress 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.